Cingulate Inc.
CINGHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and. Valued at $72.4M, CING is a micro-cap name in its sector. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Market Cap
$72.4M
Beta
-0.88
P/E (TTM)
—
P/E (Fwd)
-5.66
EPS (TTM)
$-3.51
EPS (Fwd)
$-0.88
ROE
-198.7%
ROA
-66.9%
Cash
$28.4M
Total Debt
$6.3M
Free CF
-$12.8M
52W Change
32.5%
Annual Financials
Cash vs Debt
Where CING stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CING finished 15.83% below its 150-day moving average ($5.18) and 19.71% below its 200-day moving average ($5.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CING overbought or oversold?
At the October 20, 2026 close, CING's RSI(14) was 22.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cingulate Inc. holds $28.4M in cash against $6.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$12.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -198.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.88 suggests CING is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, CING has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cingulate Inc.'s trajectory.